(Z)-2-cyclohexyl-N’-hydroxyacetimidamide

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (Z)-2-cyclohexyl-N’-hydroxyacetimidamide
• 英文别名: (Z)-2-cyclohexyl-N'-hydroxyacetimidamide；N-hydroxyCyclohexaneethanimidamide；2-cyclohexyl-N'-hydroxyethanimidamide
• 化学式: C₈H₁₆N₂O
• 分子量: 156.228
• InChiKey: NGBKKVXCFFKISP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (Z)-2-cyclohexyl-N’-hydroxyacetimidamide 、 (S)-6-((tert-butoxycarbonyl)amino)-2-(((2-(trimethylsilyl)ethoxy)carbonyl)amino)hexanoic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl (2-trimethylsilylethyl)(6-((2-cyclohexylacetimidamido)oxy)-6-oxohexane-1,5-diyl)-(S)-dicarbamate
  参考文献：
  名称：

  [EN] MITOCHONDRIA-TARGETING PEPTIDES
  [FR] PEPTIDES CIBLANT LES MITOCHONDRIES

  摘要：

  披露了用于治疗和预防缺血再灌注损伤（例如心脏缺血再灌注损伤）或心肌梗死的非天然肽。

  公开号：

  WO2019118878A1
• 作为产物：
  描述：

  1-环己基乙腈 在 盐酸羟胺 作用下， 以 乙醇 、 水 为溶剂， 反应 12.0h， 以44%的产率得到(Z)-2-cyclohexyl-N’-hydroxyacetimidamide
  参考文献：
  名称：

  [EN] MITOCHONDRIA-TARGETING PEPTIDES
  [FR] PEPTIDES CIBLANT LES MITOCHONDRIES

  摘要：

  披露了用于治疗和预防缺血再灌注损伤（例如心脏缺血再灌注损伤）或心肌梗死的非天然肽。

  公开号：

  WO2019118878A1

文献信息

• [EN] CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES<br/>[FR] DÉRIVÉS CARBOXY PRÉSENTANT DES PROPRIÉTÉS ANTI-INFLAMMATOIRES
  申请人：SITRYX THERAPEUTICS LTD

  公开号：WO2021130492A1

  公开（公告）日：2021-07-01

  The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein, RA1, RA2, RC and RD are as defined herein.

  这项发明涉及式(I)的化合物及其在治疗或预防炎症性疾病或与不良免疫反应相关的疾病中的应用：(I)其中，RA1、RA2、RC和RD如本文所定义。
• [EN] OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE<br/>[FR] COMPOSÉS OXADIAZOLE, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：PIRAMAL LIFE SCIENCES LTD

  公开号：WO2011104680A1

  公开（公告）日：2011-09-01

  The present invention relates to oxadiazole compounds in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable prodrugs and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the oxadiazole compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the treatment of cancer, particularly chronic myeloid leukemia (CML). The present invention further provides a method of treatment of cancer by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

  本发明涉及氧代唑化合物的所有立体异构体和互变异构体形式以及它们在所有比例的混合物中；以及它们的药学上可接受的盐、药学上可接受的溶剂化合物、药学上可接受的前药和药学上可接受的多形态。该发明还涉及制备氧代唑化合物的方法以及含有它们的药物组合物。所述化合物及其药物组合物可用于治疗癌症，特别是慢性髓样白血病（CML）。本发明还提供了一种治疗癌症的方法，即通过向需要的哺乳动物投予所述化合物或其药物组合物的治疗有效剂量。
• OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE
  申请人：Sivakumar Meenakshi

  公开号：US20130005771A1

  公开（公告）日：2013-01-03

  The present invention relates to oxadiazole compounds in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable prodrugs and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the oxadiazole compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the treatment of cancer, particularly chronic myeloid leukemia (CML). The present invention further provides a method of treatment of cancer by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

  本发明涉及噁唑烷化合物及其所有立体异构体、互变异构体和所有比例的混合物，以及它们的药学上可接受的盐、药学上可接受的溶剂化合物、药学上可接受的前药和药学上可接受的多型体。本发明还涉及制造噁唑烷化合物的方法以及包含它们的制药组合物。所述化合物及其制药组合物在治疗癌症，特别是慢性髓细胞白血病（CML）方面有用。本发明还提供了一种通过向需要治疗的哺乳动物中投与所述化合物或其制药组合物的治疗有效量来治疗癌症的方法。
• Styrenyl 1,2,4-oxadiazole compounds
  申请人：Sivakumar Meenakshi

  公开号：US08629277B2

  公开（公告）日：2014-01-14

  The present invention relates to oxadiazole compounds in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable prodrugs and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the oxadiazole compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the treatment of cancer, particularly chronic myeloid leukemia (CML). The present invention further provides a method of treatment of cancer by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

  本发明涉及氧代二唑化合物及其所有立体异构体、互变异构体和混合物，以及其药学上可接受的盐、药学上可接受的溶剂化物、药学上可接受的前药和药学上可接受的多型体。该发明还涉及制备氧代二唑化合物的方法以及含有它们的制药组合物。所述化合物及其制药组合物在治疗癌症，特别是慢性髓细胞白血病（CML）方面有用。本发明还提供了一种通过向需要治疗的哺乳动物中给予所述化合物或其制药组合物的治疗有效量来治疗癌症的方法。
• Structure-activity relationships of a novel class of Src SH2 inhibitors
  作者：John L. Buchanan、Chi B. Vu、Taylor J. Merry、Evelyn G. Corpuz、Selvaluxmi G. Pradeepan、Ukti N. Mani、Michael Yang、Hilary R. Plake、Vaibhav M. Varkhedkar、Berkley A. Lynch、Ian A. MacNeil、Kara A. Loiacono、Choi Lai Tiong、Dennis A. Holt

  DOI：10.1016/s0960-894x(99)00389-3

  日期：1999.8

  The structure-activity relationships (SAR) of a novel class of Src SH2 inhibitors are described. Variation at the pY+1 and pY+3 side chain positions using 2,4- and 2,5-substituted thiazoles and 1,2,4-oxadiazoles as scaffolds resulted in inhibitors that bound as well as the standard tetrapeptide Ac-pYEEI-NH2. (C) 1999 Elsevier Science Ltd. All rights reserved.